1241.36.01005 Boehringer Ingelheim Investigational Site

Calgary, Alberta

0 studies enrolling now · 1 studies all time

What they study most

Hepatitis C, Chronic

Studies at this site

• Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 — Completed